Seagen Inc (SGEN)

NASDAQ
137.72
+2.37(+1.75%)
After Hours
138.39
+0.67(+0.49%)
- Real-time Data
  • Volume:
    985,217
  • Day's Range:
    136.18 - 138.41
  • 52 wk Range:
    105.43 - 192.79

SGEN Overview

Prev. Close
135.35
Day's Range
136.18-138.41
Revenue
1.67B
Open
138.06
52 wk Range
105.43-192.79
EPS
-4.04
Volume
985,217
Market Cap
25.4B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,080,495
P/E Ratio
-43.57
Beta
0.57
1-Year Change
-14.67%
Shares Outstanding
184,435,456
Next Earnings Date
Oct 27, 2022
What is your sentiment on Seagen?
or
Market is currently closed. Voting is open during market hours.

Seagen Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Seagen Inc Analysis

Seagen Inc Company Profile

Seagen Inc Company Profile

Employees
2675

Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.

Read More

Analyst Price Target

Average183.43 (+33.19% Upside)
High220
Low150
Price137.72
No. of Analysts22
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyNeutralSellNeutral
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellSell
SummaryStrong BuyStrong BuyBuyStrong SellNeutral
  • what happened?
    0
    • azeem Malik
      1
      • The European Commission (EC) has granted marketing authorization for Seagen's (NASDAQ:SGEN) Tukysa (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.
        1
        • What is the news?
          1
          • Apprently they may be included in the S&P 500, and hence funds. Just like Tesla a few weeks back
            2
          • Ludovic Raymond Did you hold a position?
            0
        • Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021
          1
          • Price drop is the result of the #1 Institutional holder (Baker Bros) selling the entire position.
            0
            • Executing through a secondary offering. The company issued a press release on it.
              0
            • Charles Coolidge, prove it.
              0
            • Charles Coolidge, prove it.
              0
          • Seagen (SGEN) Gets Positive CHMP Opinion for Breast Cancer Drug  December 14, 2020
            0
            • 180+
              0
              • Buy buy buy
                0
                • Reports tomorrow worth a BUY? > www.tradeticker.news/sgen/
                  1